New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial
In a recent study published in the journal Nature Medicine, researchers conducted a randomized, double-blinded, placebo-controlled phase 2a trial to investigate the safety and efficacy of LM11A-31 in managing Alzheimer's disease (AD) through p75 …